All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition
William Wierda, MD Anderson Cancer Center, Houston, US, discusses the impact of novel treatment options on long-term outcomes in chronic lymphocytic leukemia (CLL). He discusses the new standard-of-care of small molecule inhibitor monotherapy, and/or with a CD20 antibody. He also mentions the exciting data on combination approaches utilizing BCL-2 inhibitors with BTK inhibitors which have been shown to induce very good deep remissions in the majority of patients, so much so that it may be possible to consider discontinuing therapy.
Impact of novel treatment options on long-term outcomes in CLL and WM
SOHO 2019 | A standard of care (SoC) update for chronic lymphocytic leukemia (CLL)
Exciting data for the frontline treatment of CLL have been published in the last year, shifting the SoC from chemoimmunotherapy-based regimens towards small-molecule...
ASCO 2018 | The Highlights
Did you miss ASCO 2018? The Lymphoma Hub has developed a downloadable resource which provides a summary of the key presentations in lymphoma and CLL at the ASCO 2018 annual meeting, Chicago, June 1-5
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox